# Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

> **NCT00045136** · PHASE1,PHASE2 · COMPLETED · sponsor: **Poniard Pharmaceuticals**

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** melphalan
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** holmium Ho 166 DOTMP

## Key facts

- **NCT ID:** NCT00045136
- **Lead sponsor:** Poniard Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2003-01
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045136, "Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00045136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*